Corrigendum to: Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster

Corrigendum to: Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster

Saved in:

Bibliographic Details
Main Authors:	Jun Liu, Jing Sun, Liping Luo, Yanhong Tang, Hu Guo, Yiyun He, Qi Liu, Xuya Yu, Yumei Huang, Siyuan Zhang, Airu Zhu, Jun Dai, Fan Zhang, Tao Huang, Jincun Zhao, Yucai Peng
Format:	Article
Language:	English
Published:	Compuscript Ltd 2025-02-01
Series:	Zoonoses
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2025-1001
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
by: Jun Liu, et al.
Published: (2024-04-01)

Clinical characteristics and booster vaccine effectiveness of the Omicron variant
by: Lijun Sun, et al.
Published: (2024-11-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Neutralizing antibody responses to SARS-CoV-2 variants after COVID-19 vaccination and boosters
by: Kabita Adhikari, et al.
Published: (2025-06-01)

Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines
by: Canjie Chen, et al.
Published: (2024-12-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
by: F. D. Partey, et al.
Published: (2025-07-01)

Circulating Antibodies Against Common Cold Coronaviruses Do Not Interfere with Immune Responses to Primary or Booster SARS-CoV-2 mRNA Vaccines
by: Bindu Adhikari, et al.
Published: (2025-05-01)

Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates
by: Dongrong Yi, et al.
Published: (2025-02-01)

In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models
by: Peilan Wei, et al.
Published: (2025-12-01)

Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation
by: Dorit Fabricius, et al.
Published: (2025-05-01)

Comparable immune escape capacity between KP.2 and other SARS-CoV-2 variants in the central Chinese population after the first COVID-19 booster
by: Youhua Yuan, et al.
Published: (2025-05-01)

Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study
by: Wataru Mimura, et al.
Published: (2024-12-01)

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency
by: S. A. Berns, et al.
Published: (2023-12-01)

SARS-CoV-2 vaccine boosters: The time to act is now.
by: Maya Petersen, et al.
Published: (2021-12-01)

Corrigendum: Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming
by: Yenni Yusuf, et al.
Published: (2025-04-01)

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
by: Tjalf Ziemssen, et al.
Published: (2024-12-01)

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
by: Tjalf Ziemssen, et al.
Published: (2023-08-01)

mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice
by: Xiaoming Liang, et al.
Published: (2025-01-01)

Using surveillance data to evaluate the effectiveness of inactivated/mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the current ambit of SARS-CoV-2 XBB and JN.1 variant circulation
by: Eugene S. K. Lo, et al.
Published: (2025-05-01)

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial
by: Shipo Wu, et al.
Published: (2025-08-01)

Immunogenicity of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, in different booster settings
by: Yoshiaki Oda, et al.
Published: (2025-08-01)

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
by: Ramandip Grewal, et al.
Published: (2024-12-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster
by: Yun Sang Tang, et al.
Published: (2024-12-01)

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
by: Joel Sop, et al.
Published: (2025-03-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice
by: Reshma Koolaparambil Mukesh, et al.
Published: (2025-07-01)

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants
by: Abhinay Gontu, et al.
Published: (2025-06-01)

Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection
by: Veronika Vaňová, et al.
Published: (2025-05-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea
by: Seok-Kyoung Choi, et al.
Published: (2024-12-01)

Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
by: Ricardo da Silva Antunes, et al.
Published: (2025-07-01)

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity
by: Jernej Pušnik, et al.
Published: (2024-11-01)

Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
by: Ana C. Montagud, et al.
Published: (2025-01-01)

Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model
by: Tong Yu, et al.
Published: (2025-05-01)

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster dosesResearch in context
by: Annalisa Ciabattini, et al.
Published: (2025-03-01)

Safety and Immunogenicity of Pfizer BioNTech mRNA Vaccine and Novavax NVX-CoV2373 COVID-19 Mix and Match Booster Vaccination in Adolescents Aged 12-17 Years with HIV infection in Kenya
by: Dr Lucas Tina, et al.
Published: (2025-03-01)

Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
by: Napon Hiranburana, et al.
Published: (2025-01-01)

Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
by: Mijeong Ko, et al.
Published: (2024-08-01)